RxDoctor Payments Data

Allison Pernic, MD

Ophthalmology · Warsaw, INNPI 1497070957

Payments from drug & device makers

$1,602in general payments, 2019–2025

Across 63 payments — averaging $25.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$397
  • AbbVie$222
  • Genentech USA, Inc.$190
  • Novartis$151
  • Glaukos Corporation$144
  • Rxsight Inc$87
  • plus $412 from 14 others

What the payments were for

  • Food & beverage$1,602100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,602 in reported general payments places this provider in the 50th percentile of 266 ophthalmology providers in Indiana.

See all ophthalmology providers in Indiana

Medicare billing

Part B allowed, 2024
$1,593,106
Medicare patients
891
Services billed
11,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost54$27,151
RocklatanNetarsudil Mesylat/Latanoprost41$18,208
RhopressaNetarsudil Mesylate33$11,445
SimbrinzaBrinzolamide/Brimonidine Tart35$8,303
Prednisolone Acetate182$7,827
CombiganBrimonidine Tartrate/Timolol19$5,993
Brimonidine Tartrate160$5,072
Latanoprost649$4,106
Diclofenac Sodium165$2,911
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol26$2,545
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat188$1,612
Travoprost20$1,612
Timolol Maleate158$1,537
Fluorometholone13$911
Dorzolamide Hcl53$896

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan$222$33,14473 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$16$29,65374 claims
AlconSimbrinza$397$8,30335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 266 ophthalmology providers in Indiana.

Other ophthalmology in Warsaw

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →